Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.550
-0.290 (-5.99%)
At close: Nov 20, 2024, 4:00 PM
4.560
+0.010 (0.22%)
After-hours: Nov 20, 2024, 4:36 PM EST
Verve Therapeutics Stock Forecast
VERV's stock price has decreased by -61.21% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 25.75, with a low estimate of 14 and a high estimate of 40. The average target predicts an increase of 465.93% from the current stock price of 4.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for VERV stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $29 → $32 | Strong Buy | Maintains | $29 → $32 | +603.30% | Nov 6, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +273.63% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +207.69% | Nov 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $30 → $29 | Strong Buy | Maintains | $30 → $29 | +537.36% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +229.67% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
21.71M
from 11.76M
Increased by 84.66%
Revenue Next Year
12.69M
from 21.71M
Decreased by -41.58%
EPS This Year
-2.59
from -3.12
EPS Next Year
-3.00
from -2.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.1M | 28.8M | 25.8M | ||
| Avg | 21.7M | 12.7M | 8.7M | ||
| Low | 12.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 164.5% | 32.8% | 103.6% | ||
| Avg | 84.7% | -41.6% | -31.2% | ||
| Low | 3.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.44 | -2.39 | -2.12 | ||
| Avg | -2.59 | -3.00 | -2.99 | ||
| Low | -2.90 | -3.54 | -3.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.